FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Josep Tabernero

Research Profile

Procedures

Disorders

Chemicals & Drugs

Concepts & Ideas

Anatomy

Tumor Cell Line

Physiology

Signal Transduction

Co-author Network

Publications

TOP 3
Pier Davide Angelini; José Baselga; Cristina Bernadó Morales; Francesc Canals; Jordi Giralt; Roger R Gomis; Marc Guiu; Antonio Luque-García; Nerea Peiró Navalpotro; Josep Lluís Parra-Palau; Kim Pedersen; Josep Tabernero; Rocio Vicario; Josep Villanueva; Mariano F Zacarias Fluck; Joaquín Arribas
Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.
Aimery de Gramont; J Randolph Hecht; Thierry André; Emilio Bajetta; György Bodoky; Thomas H Cartwright; Stephen Clarke; David Cunningham; Seock-Ah Im; Frédérique Maindrault-Goebel; Martina Makrutzki; Malcolm J Moore; Fernando Rivera; Ramon Salazar; Hans-Joachim Schmoll; Einat Shacham-Shmueli; Aijing Shang; Josep Tabernero; Eric Van Cutsem; Paulo M Hoff
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
G Argilés; J Rodon; Josep Tabernero
Depicting the evolving scenario of translational-guided drug development.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Josep Tabernero (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Pier Davide Angelini; José Baselga; Cristina Bernadó Morales; Francesc Canals; Jordi Giralt; Roger R Gomis; Marc Guiu; Antonio Luque-García; Nerea Peiró Navalpotro; Josep Lluís Parra-Palau; Kim Pedersen; Josep Tabernero; Rocio Vicario; Josep Villanueva; Mariano F Zacarias Fluck; Joaquín Arribas
Constitutive HER2 signaling promotes breast cancer metastasis through cellular senescence.
Cancer research 2013;73(1):450-8.
2012: Aimery de Gramont; J Randolph Hecht; Thierry André; Emilio Bajetta; György Bodoky; Thomas H Cartwright; Stephen Clarke; David Cunningham; Seock-Ah Im; Frédérique Maindrault-Goebel; Martina Makrutzki; Malcolm J Moore; Fernando Rivera; Ramon Salazar; Hans-Joachim Schmoll; Einat Shacham-Shmueli; Aijing Shang; Josep Tabernero; Eric Van Cutsem; Paulo M Hoff
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.
The lancet oncology 2012;13(12):1225-33.
2012: G Argilés; J Rodon; Josep Tabernero
Depicting the evolving scenario of translational-guided drug development.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2012;14(12):881-2.
2012: Christophe Tournigand; Thierry André; Jean-Baptiste Bachet; Corrado Boni; Franck bonnetain; Benoist Chibaudel; Tamas Hickish; Gérard Lledo; Josep Tabernero; Luis Teixeira; Aimery de Gramont
Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2012;30(27):3353-60.
2012: Austin M Dulak; Peter C Enzinger; Cameron Fox; Tony E Godfrey; Yu Imamura; Lin Lin; James D Luketich; Matthew Meyerson; Shuji Ogino; Arjun Pennathur; Alex H Ramos; franco roviello; Gordon Saksena; Steven E Schumacher; Byoungyong Shim; Ramesh A Shivdasani; Josep Tabernero; Jasper van Lieshout; Sylvan C Baca; Santhoshi Bandla; Jordi Barretina; Jose Baselga; David G Beer; Rameen Beroukhim; Giovanni Corso; Adam J Bass
Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis.
Cancer research 2012;72(17):4383-93.
2012: René Adam; Aimery de Gramont; Joan Figueras; Ashley Guthrie; Norihiro Kokudo; Francis Kunstlinger; Evelyne Loyer; Graeme Poston; Philippe Rougier; Laura Rubbia-Brandt; Alberto Sobrero; Josep Tabernero; Catherine Teh; Eric Van Cutsem
The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus.
The oncologist 2012;17(10):1225-39.
2011: Carlos Gómez-Martín; Manuel Hidalgo; Josep Tabernero; Dolores Isla
SEOM clinical guidelines for the treatment of pancreatic cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2011;13(8):528-35.
2011: Daniel G Haller; Josep Tabernero; Jean Maroun; Filippo de Braud; Timothy Price; Eric Van Cutsem; Mark Hill; Frank Gilberg; Karen Rittweger; Hans-Joachim Schmoll
Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(11):1465-71.
2011: Rodrigo Dienstmann; Eduardo Vilar; Josep Tabernero
Molecular predictors of response to chemotherapy in colorectal cancer.
Cancer journal (Sudbury, Mass.) 2011;17(2):114-26.
2011: Enrique Aranda; Albert Abad; Alfredo Carrato; Andrés Cervantes; Jesús García-Foncillas; Pilar García Alfonso; Rocío García Carbonero; Auxiliadora Gómez España; Josep Tabernero; Eduardo Díaz-Rubio
Treatment recommendations for metastatic colorectal cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2011;13(3):162-78.
2011: Eduardo Vilar; Jose Perez-Garcia; Josep Tabernero
Pushing the envelope in the mTOR pathway: the second generation of inhibitors.
Molecular cancer therapeutics 2011;10(3):395-403.
2011: Arijit Chakravarty; Vaishali Shinde; Josep Tabernero; Andres Cervantes; Roger B Cohen; E Claire Dees; Howard Burris; Jeffrey R Infante; Teresa Macarulla; Elena Elez; Jordi Andreu; Edith Rodriguez-Braun; Susana Rosello; Margaret von Mehren; Neal J Meropol; Corey J Langer; Bert ONeil; Douglas Bowman; Mengkun Zhang; Hadi Danaee; Laura Faron-Yowe; Gary Gray; Hua Liu; Jodi Pappas; Lee Silverman; Chris Simpson; Bradley Stringer; Stephen Tirrell; Ole Petter Veiby; Karthik Venkatakrishnan; Katherine Galvin; Mark Manfredi; Jeffrey A Ecsedy
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase.
Cancer research 2011;71(3):675-85.
2011: J Capdevila; I Díez Miranda; G Obiols; Josep Tabernero
Control of carcinoid syndrome with everolimus.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2011;22(1):237-9.
2010: Heinz Zwierzina; Alberto Bardelli; Fortunato Ciardiello; Manuela Gariboldi; Leif Håkansson; Diether Lambrechts; Guro E Lind; Judith Loeffler-Ragg; Hans Schmoll; Salvatore Siena; Josep Tabernero; Eric Van Cutsem
Molecularly targeted therapies for colorectal cancer: Strategies for implementing translational research in clinical trials.
Current opinion in molecular therapeutics 2010;12(6):703-11.
2010: Rodrigo Dienstmann; Josep Tabernero
Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer.
Current opinion in investigational drugs (London, England : 2000) 2010;11(12):1434-41.
2010: Ben Markman; Rodrigo Dienstmann; Josep Tabernero
Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.
Oncotarget 2010;1(7):530-43.
2010: Mark M Pomerantz; Yashaswi Shrestha; Richard Flavin; Meredith M Regan; Kathryn L Penney; Lorelei A Mucci; Meir J Stampfer; David J Hunter; STEPHEN CHANOCK; Eric J Schafer; Jennifer A Chan; Josep Tabernero; José Baselga; Andrea L Richardson; Massimo Loda; William K Oh; Philip W Kantoff; William C Hahn; Matthew L Freedman
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis.
PLoS genetics 2010;6(11):e1001204.
2010: José Baselga; Andres Cervantes; Erika Martinelli; Isabel Chirivella; Klaas Hoekman; Herbert I Hurwitz; Duncan I Jodrell; Paul Hamberg; Esther Casado; Paul Elvin; Alan Swaisland; Renee Iacona; Josep Tabernero
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(19):4876-83.
2010: Josep Tabernero; José Baselga
Multigene assays to improve assessment of recurrence risk and benefit from chemotherapy in early-stage colon cancer: has the time finally arrived, or are we still stage locked?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(25):3904-7.
2010: Federica Di Nicolantonio; Sabrina Arena; Josep Tabernero; Stefano Grosso; Francesca Molinari; Teresa Macarulla; Mariangela Russo; Carlotta Cancelliere; Davide Zecchin; Luca Mazzucchelli; Takehiko Sasazuki; Senji Shirasawa; Massimo Geuna; Milo Frattini; José Baselga; Margherita Gallicchio; Stefano Biffo; Alberto Bardelli
Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus.
The Journal of clinical investigation 2010;120(8):2858-66.
2010: Wendy De Roock; Bart Claes; David Bernasconi; Jef De Schutter; Bart Biesmans; George Fountzilas; Konstantine T Kalogeras; Vassiliki Kotoula; Demetris Papamichael; Pierre Laurent-Puig; Frédérique Penault-Llorca; Philippe Rougier; Bruno Vincenzi; Daniele Santini; Giuseppe Tonini; Federico Cappuzzo; Milo Frattini; Francesca Molinari; Piercarlo Saletti; Sara De Dosso; Miriam Martini; Alberto Bardelli; Salvatore Siena; Andrea Sartore-Bianchi; Josep Tabernero; Teresa Macarulla; Frédéric Di Fiore; Alice Oden Gangloff; Fortunato Ciardiello; Per Pfeiffer; Camilla Qvortrup; Tine Plato Hansen; Eric Van Cutsem; Hubert Piessevaux; Diether Lambrechts; Mauro Delorenzi; Sabine Tejpar
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.
The lancet oncology 2010;11(8):753-62.
2010: René Adam; D G Haller; G Poston; J-L Raoul; J-P Spano; Josep Tabernero; E Van Cutsem
Toward optimized front-line therapeutic strategies in patients with metastatic colorectal cancer--an expert review from the International Congress on Anti-Cancer Treatment (ICACT) 2009.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(8):1579-84.
2010: B Markman; V Rodríguez-Freixinos; Josep Tabernero
Biomarkers in colorectal cancer.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2010;12(4):261-70.
2010: Rameen Beroukhim; Craig H Mermel; Dale Porter; Guo Wei; Soumya Raychaudhuri; Jerry Donovan; Jordi Barretina; Jesse S Boehm; Jennifer Dobson; Mitsuyoshi Urashima; Kevin T Mc Henry; Reid M Pinchback; Azra H Ligon; Yoon-Jae Cho; Leila Haery; Heidi Greulich; Michael Reich; Wendy Winckler; Michael S Lawrence; Barbara A Weir; Kumiko E Tanaka; Derek Chiang; Adam J Bass; Alice Loo; Carter Hoffman; John Prensner; Ted Liefeld; Qing Gao; Derek Yecies; Sabina Signoretti; Elizabeth Maher; Frederic J Kaye; Hidefumi Sasaki; Joel E Tepper; Jonathan A Fletcher; Josep Tabernero; José Baselga; Ming-Sound Tsao; Francesca Demichelis; Mark A Rubin; Pasi A Janne; Mark J Daly; Carmelo Nucera; Ross Levine; Benjamin L Ebert; Stacey Gabriel; Anil K Rustgi; Cristina R Antonescu; Marc Ladanyi; Anthony Letai; Levi A Garraway; Massimo Loda; David G Beer; Lawrence True; Aikou Okamoto; Scott L Pomeroy; Samuel Singer; Todd R Golub; Eric S Lander; Gad Getz; William R Sellers; Matthew Meyerson
The landscape of somatic copy-number alteration across human cancers.
Nature 2010;463(7283):899-905.
2010: ramon colomer; E Alba; A González-Martin; L Paz-Ares; M Martín; A Llombart; A Rodríguez Lescure; J Salvador; J Albanell; D Isla; M Lomas; C A Rodríguez; J M Trigo; J R Germà; J Bellmunt; Josep Tabernero; R Rosell; E Aranda; R Cubedo; J Baselga
Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2010;21(2):195-8.
2010: Aimery de Gramont; Daniel G Haller; Daniel J Sargent; Josep Tabernero; Alastair Matheson; Richard L Schilsky
Toward efficient trials in colorectal cancer: the ARCAD Clinical Trials Program.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(4):527-30.
2009: Josep Tabernero; Teresa Macarulla
Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(33):5487-91.
2009: Richard M Goldberg; Neal J Meropol; Josep Tabernero
Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer.
Gastrointestinal cancer research : GCR 2009;3(5 Supplement 2):S23-7.
2009: Mark M Pomerantz; Nasim Ahmadiyeh; Li Jia; Paula Herman; Michael P Verzi; Harshavardhan Doddapaneni; Christine A Beckwith; Jennifer A Chan; Adam Hills; Matt Davis; Keluo Yao; Sarah M Kehoe; Heinz-Josef Lenz; Christopher A Haiman; Chunli Yan; Brian E Henderson; Baruch Frenkel; Jordi Barretina; Adam Bass; Josep Tabernero; José Baselga; Meredith M Regan; J Robert Manak; Ramesh A Shivdasani; Gerhard A Coetzee; Matthew L Freedman
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer.
Nature genetics 2009;41(8):882-4.
2009: Thierry André; Corrado Boni; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Andrea Bonetti; Philip Clingan; John Bridgewater; Fernando Rivera; Aimery de Gramont
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(19):3109-16.
2009: Manuel Hidalgo; A Abad; E Aranda; L Díez; J Feliu; C Gómez; A Irigoyen; R López; F Rivera; C Rubio; J Sastre; Josep Tabernero; E Díaz-Rubio
Consensus on the treatment of pancreatic cancer in Spain.
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2009;11(5):290-301.
2009: Patrick Schöffski; Vincente Guillem; Margarita Garcia; Fernando Rivera; Josep Tabernero; Martin Cullell; Jose A Lopez-Martin; Patricia Pollard; Herlinde Dumez; Xavier Garcia del Muro; Luis Paz-Ares
Phase II randomized study of Plitidepsin (Aplidin), alone or in association with L-carnitine, in patients with unresectable advanced renal cell carcinoma.
Marine drugs 2009;7(1):57-70.
2008: Jordi Giralt; Josep Tabernero; Begoña Navalpotro; Jaume Capdevila; Eloi Espin; Esther Casado; Anabel Mañes; Stefania Landolfi; Jose Luis Sanchez-Garcia; Ines de Torres; Manel Armengol
Pre-operative chemoradiotherapy with UFT and Leucovorin in patients with advanced rectal cancer: a phase II study.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2008;89(3):263-9.
2008: E Vilar; M Scaltriti; J Balmaña; Carlos A Saura; M Guzman; J Arribas; J Baselga; Josep Tabernero
Microsatellite instability due to hMLH1 deficiency is associated with increased cytotoxicity to irinotecan in human colorectal cancer cell lines.
British journal of cancer 2008;99(10):1607-12.
2008: Albert Font; Ramon Salazar; Joan Maurel; Miquel Taron; Jose Luis Ramirez; Josep Tabernero; Rosa Gallego; Esther Casado; Jose Luis Manzano; Enric Carcereny; Marta Guix; Jaume Fernández-Llamazares; Rafael Rosell
Cisplatin plus weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
Cancer chemotherapy and pharmacology 2008;62(6):1075-83.
2008: Ron Firestein; Adam J Bass; So Young Kim; Ian F Dunn; Serena J Silver; Isil Guney; Ellen Freed; Azra H Ligon; Natalie Vena; Shuji Ogino; Milan G Chheda; Pablo Tamayo; Stephen Finn; Yashaswi Shrestha; Jesse S Boehm; Supriya Jain; Emeric Bojarski; Craig Mermel; Jordi Barretina; Jennifer A Chan; Jose Baselga; Josep Tabernero; David E Root; Charles S Fuchs; Massimo Loda; Ramesh A Shivdasani; Matthew Meyerson; William C Hahn
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity.
Nature 2008;455(7212):547-51.
2008: M Bouchahda; T Macarulla; J P Spano; J B Bachet; G Lledo; T Andre; B Landi; Josep Tabernero; A Karaboué; J Domont; F Levi; P Rougier
Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.
Critical reviews in oncology/hematology 2008;67(3):255-62.
2008: Teresa Macarulla; Francisco Javier Ramos; Josep Tabernero
Aurora kinase family: a new target for anticancer drug.
Recent patents on anti-cancer drug discovery 2008;3(2):114-22.
2008: Daniel G Haller; Jim Cassidy; Stephen J Clarke; David Cunningham; Eric Van Cutsem; Paulo M Hoff; Mace L Rothenberg; Leonard B Saltz; Hans-Joachim Schmoll; Carmen Allegra; Joseph R Bertino; Jean-Yves Douillard; Bengt G Gustavsson; Gerard Milano; Michael O'Connell; Youcef Rustum; Josep Tabernero; Frank Gilberg; Florin Sirzén; Chris Twelves
Potential regional differences for the tolerability profiles of fluoropyrimidines.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(13):2118-23.
2008: Jose Baselga; Mace L Rothenberg; Josep Tabernero; Joan Seoane; Thomas Daly; Ann Cleverly; Brandi Berry; Susanne K Rhoades; Chad A Ray; Jeffrey Fill; Daphne L Farrington; Lisa Anne Wallace; Jonathan M Yingling; Michael Lahn; Carlos L Arteaga; Michael A Carducci
TGF-beta signalling-related markers in cancer patients with bone metastasis.
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2008;13(2):217-36.
2008: Albert Abad; Bartomeu Massuti; Antonio Antón; Maria Eugenia Vega; Ana L Yuste; Eugenio Marcuello; José Luis Manzano; Vicente Alonso; Alfredo Carrato; Mercedes Martinez-Villacampa; Josep Tabernero; Enrique Aranda; Fernando Rivera; Eduardo Díaz-Rubio
Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study.
Acta oncologica (Stockholm, Sweden) 2008;47(2):286-92.
2007: José Baselga; Josep Tabernero
Combined antiangiogenesis and antiepidermal growth factor receptor targeting in the treatment of cancer: hold back, we are not there yet.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(29):4516-8.
2007: Eva Thomas; Josep Tabernero; Monica Fornier; Pierfranco Conté; Pierre Fumoleau; Ana Lluch; Linda Vahdat; Craig A Bunnell; Howard A Burris; Patrice Viens; José Baselga; Edgardo Rivera; Valentina Guarneri; Valerie Poulart; Judith Klimovsky; David Lebwohl; Miguel Martin
Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(23):3399-406.
2007: Hans-Joachim Schmoll; Thomas Cartwright; Josep Tabernero; Marek P Nowacki; Arie Figer; Jean Maroun; Timothy Price; Robert Lim; Eric Van Cutsem; Young-Suk Park; Joseph McKendrick; Claire Topham; Gemma Soler-Gonzalez; Filipo de Braud; Mark Hill; Florin Sirzén; Daniel G Haller
Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):102-9.
2006: Enrique Aranda; Albert Abad; Alfredo Carrato; Andrés Cervantes; Josep Tabernero; Eduardo Díaz-Rubio
Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy).
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2006;8(2):98-102.
2004: Pablo Matar; Federico Rojo; Raúl Cassia; Gema Moreno-Bueno; Serena Di Cosimo; Josep Tabernero; Marta Guzmán; Sonia Rodriguez; Joaquín Arribas; José Palacios; José Baselga
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6487-501.
2004: Thierry André; Corrado Boni; Lamia Mounedji-Boudiaf; Matilde Navarro; Josep Tabernero; Tamas Hickish; Clare Topham; Marta Zaninelli; Philip Clingan; John Bridgewater; Isabelle Tabah-Fisch; Aimery de Gramont
Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.
The New England journal of medicine 2004;350(23):2343-51.
2004: M Martin-Richard; M Muñoz; Joan Albanell; Lluís Colomo; M Bellet; María Jesús Rey; Josep Tabernero; C Alonso; Antonio Cardesa; Pere Gascon; Pedro L Fernandez
Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy.
Oncology 2004;66(5):388-94.
2003: Bart C Kuenen; Josep Tabernero; Jose Baselga; Franco Cavalli; Elisabeth Pfanner; Pier Franco Conte; Siegfried Seeber; Srinivasan Madhusudan; Gael Deplanque; Holgen Huisman; Paul Scigalla; Klaas Hoekman; Adrian L Harris
Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1648-55.
2001: José Baselga; Josep Tabernero
Weekly docetaxel in breast cancer: applying clinical data to patient therapy.
The oncologist 2001;6 Suppl 3():26-9.
1999: Ramón Salazar; C Solá; Pablo Maroto; Josep Tabernero; Joan Brunet; G Verger; Vicente Valentí; J A Cancelas; Belén Ojeda; L Mendoza; M Rodríguez; José Luis Montesinos; Juan José López López
Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation.
Bone marrow transplantation 1999;23(1):27-33.
1996: J Mora; N Gascón; Josep Tabernero; José Rodríguez-Espinosa; Francesc González-Sastre
Different hCG assays to measure ectopic hCG secretion in bladder carcinoma patients.
British journal of cancer 1996;74(7):1081-4.